Abstract
Coronavirus disease 2019 (COVID-19) displays high clinical variability but the parameters that determine disease severity are still unclear. Pre-existing T cell memory has been hypothesized as a protective mechanism but conclusive evidence is lacking. Here we demonstrate that all unexposed individuals harbor SARS-CoV-2-specific memory T cells with marginal cross-reactivity to common cold corona and other unrelated viruses. They display low functional avidity and broad protein target specificities and their frequencies correlate with the overall size of the CD4+ memory compartment reflecting the immunological age of an individual. COVID-19 patients have strongly increased SARS-CoV-2-specific inflammatory T cell responses that are correlated with severity. Strikingly however, patients with severe COVID-19 displayed lower TCR functional avidity and less clonal expansion. Our data suggest that a low avidity pre-existing T cell memory negatively impacts on the T cell response quality against neoantigens such as SARS-CoV-2, which may predispose to develop inappropriate immune reactions especially in the elderly. We propose the immunological age as an independent risk factor to develop severe COVID-19.
Competing Interest Statement
P.B., A.S. are consultants of Miltenyi Biotec, who own IP rights concerning parts of the ARTE technology. P.K. has received non-financial scientific grants from Miltenyi Biotec GmbH, Bergisch Gladbach, Germany, and the Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases, University of Cologne, Cologne, Germany, and received lecture honoraria from or is advisor to Akademie für Infektionsmedizin e.V., Astellas Pharma, the European Confederation of Medical Mycology, Gilead Sciences, GPR Academy Ruesselsheim, MSD Sharp & Dohme GmbH, Noxxon N.V., and University Hospital, LMU Munich outside the submitted work. O.A.C. is supported by the German Federal Ministry of Research and Education, is funded by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) under Germany's Excellence Strategy: CECAD, EXC 2030-390661388 and has received research grants from, is an advisor to, or received lecture honoraria from Actelion, Allecra, Amplyx, Astellas, Basilea, Biosys, Cidara, Da Volterra, Entasis, F2G, Gilead, Grupo Biotoscana, IQVIA,Janssen, Matinas, Medicines Company, MedPace, Melinta, Menarini, Merck/MSD, Mylan, Nabriva, Noxxon, Octapharma, Paratek, Pfizer, PSI, Roche Diagnostics, 441 Scynexis, and Shionogi. FL is supported by German Ministry of Education and Research (01GM1908A) and E-Rare Joint Transnational research support (ERA-Net, LE3064/2-1) and discloses speaker honoraria from Grifols, Teva, Biogen, Bayer, Roche, Novartis, Fresenius, travel funding from Merck, Grifols and Bayer and serving on advisory boards for Roche, Biogen and Alexion.
Funding Statement
This research was supported by the German Research Foundation (DFG) under Germanys Excellence Strategy-EXC 2167-390884018 Precision Medicine in Chronic Inflammation (to 413 P.B., A.F., A.S.) and CECAD, EXC 2030-390661388 (to O.A.C.); RU5042-miTarget to P.B., A.F.; DFG grant n. 4096610003 to E.R; FL and DE were supported by the E-Rare Joint Transnational research support (ERA-Net, LE3064/2-415 1). FL is supported by German Ministry of Education and Research (01GM1908A) and E-Rare Joint Transnational research support (ERA-Net, LE3064/2-1)
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the Institutional Review board of the UKSH Kiel (Identifier D474/20), the University Hospital Frankfurt (Identifier 11/17) and patients were enrolled in the protocol Coronavirus Disease 19-BioMaSOTA-Genetic factors and longitudinal monitoring of the immune response in COVID-19 (Identifier of the University of Cologne Ethics Committee 20-1295) and Improving Diagnosis of Severe Infections of Immunocompromised Patients (Identifier of the University of Cologne Ethics Committee 08-160) and signed informed consents.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Authors can confirm that all relevant data are included in the article and/or its supplementary information files
